NCT07057895Completed
Diagnostic Consistency of GLIM and PG-SGA for Malnutrition in Pancreatic Cancer
Diagnostic Consistency of the Global Leadership Initiative on Malnutrition (GLIM) Criteria and the Patient-Generated Subjective Global Assessment (PG-SGA) for Malnutrition in Patients With Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 10 Jul 2025
Brief summary (registry, in English)
This study aimed to evaluate the diagnostic consistency between the Global Leadership Initiative on Malnutrition (GLIM) criteria and the Patient-Generated Subjective Global Assessment (PG-SGA) for identifying malnutrition in patients with pancreatic malignant tumors. The goal is to determine if the GLIM criteria, a newer and more streamlined tool, shows substantial agreement with the well-established PG-SGA, thereby supporting its use in this high-risk clinical population.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 108 (actual)
- First submitted
- 1 Jul 2025
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- The First Hospital of Hebei Medical University
- Diseases
- Pancreatic cancer
- NCT number
- NCT07057895
What you commit to
- Study type: Interventional
- Participants enrolled: 108
- From 1 Jan 2023 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent diagnosis of other malignant tumors, particularly of the digestive system.
Other illness
- Presence of severe cardiac, hepatic, or renal comorbidities.
Other
- Bedridden status precluding weight measurement.
- Contraindications to bioelectrical impedance analysis (e.g., implanted electronic devices, amputation).
- Inability to cooperate with questionnaire completion or assessments.
Who the study is looking for
- Histopathologically confirmed pancreatic malignant tumor.
- Age ≥ 18 years.
- Clear cognition and ability to communicate verbally.
- Nutritional Risk Screening 2002 (NRS 2002) score ≥ 3.
- Provision of written informed consent to participate.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Hospital of Hebei Medical University Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.